SEARCH

SEARCH BY CITATION

References

  • 1
    Saraheimo M, Forsblom C, Fagerudd J et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 14104.
  • 2
    Saraheimo M, Forsblom C, Thorn L et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008; 31: 11659.
  • 3
    Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 178492.
  • 4
    Ouedraogo R, Wu X, Xu SQ et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55: 18406.
  • 5
    Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 2430.
  • 6
    Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008; 121: 32630.
  • 7
    Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003; 46: 14027.
  • 8
    Jorsal A, Tarnow L, Frystyk J et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008; 74: 64954.
  • 9
    Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48: 19118.
  • 10
    Hadjadj S, Aubert R, Fumeron F et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 2005; 48: 108892.
  • 11
    Groop PH, Thomas MC, Moran JL et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58: 16518.
  • 12
    Costacou T, Zgibor JC, Evans RW et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005; 48: 418.
  • 13
    Maahs DM, Ogden LG, Kinney GL et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 74753.
  • 14
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1266.
  • 15
    Force ICGT. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
  • 16
    Hoybye C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol 2004; 151: 45761.
  • 17
    Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
  • 18
    Pintilie M. Competing Risks: A Practical Perspective. Chichester, UK: John Wiley & Sons Ltd, 2006.
  • 19
    Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 2007; 83: 158692.
  • 20
    Kuha J. AIC and BIC. Comparisons of assumptions and performance. Sociol Methods Res 2005; 33: 188229.
  • 21
    Royston P, Sauerbrei W. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, West Sussex: John Wiley & Sons Ltd, 2008.
  • 22
    Belsley D. Conditioning Diagnostics, Collinearity and Weak Data in Regression. New York: Wiley, 1991.
  • 23
    Therneau T, Grambsh PM. Modelling Survival Data: Extending the Cox Model. New York: Springer-Verlag, 2000.
  • 24
    Harrell Jr F, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 36187.
  • 25
    Royston P. Explained variation for survival models. Stata J 2006; 6: 8396.
  • 26
    Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007; 30: 23944.
  • 27
    Seino Y, Hirose H, Saito I, Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 2007; 56: 14939.
  • 28
    Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 7681.
  • 29
    Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs. Am J Hypertens 2009; 22: 11269.
  • 30
    Sattar N, Watt P, Cherry L, Ebrahim S, Davey Smith G, Lawlor DA. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case–control study. J Clin Endocrinol Metab 2008; 93: 18469.
  • 31
    Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 1517.
  • 32
    Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599606.
  • 33
    Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 175662.
  • 34
    Pilz S, Mangge H, Wellnitz B et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91: 427786.
  • 35
    Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 15107.
  • 36
    Kaas A, Pfleger C, Hansen L et al. Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis. Clin Exp Immunol 2010; 161: 44452.
  • 37
    Pfleger C, Mortensen HB, Hansen L et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008; 57: 92937.
  • 38
    Ljubic S, Boras J, Jazbec A et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32: E2719.
  • 39
    Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 15959.
  • 40
    Looker HC, Krakoff J, Funahashi T et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 40107.
  • 41
    Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93: 3299301.
  • 42
    Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008; 93: 335764.
  • 43
    Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C, Sweeney G. Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects. J Clin Endocrinol Metab 2007; 92: 43138.
  • 44
    Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW. The valuable contribution of observational studies to nephrology. Kidney Int 2007; 72: 6715.